Blueprint Medicines Corp (NASDAQ:BPMC) insider Ariel Hurley sold 830 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $94.98, for a total value of $78,833.40. Following the completion of the sale, the insider now owns 830 shares in the company, valued at approximately $78,833.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Ariel Hurley also recently made the following trade(s):
- On Monday, June 17th, Ariel Hurley sold 1,405 shares of Blueprint Medicines stock. The shares were sold at an average price of $98.22, for a total value of $137,999.10.
- On Thursday, June 13th, Ariel Hurley sold 2,733 shares of Blueprint Medicines stock. The shares were sold at an average price of $88.04, for a total value of $240,613.32.
Shares of Blueprint Medicines stock opened at $98.24 on Friday. Blueprint Medicines Corp has a one year low of $44.58 and a one year high of $100.76. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27. The company’s 50-day simple moving average is $91.39. The company has a market cap of $4.71 billion, a price-to-earnings ratio of -18.23 and a beta of 1.55.
A number of equities research analysts have commented on BPMC shares. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd. ValuEngine upgraded Ultrapar Participacoes from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 4th. Robert W. Baird initiated coverage on Blueprint Medicines in a research report on Thursday. They set an “outperform” rating on the stock. Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Monday, June 17th. Finally, Goldman Sachs Group upgraded Lenovo Group from a “neutral” rating to a “buy” rating in a research report on Thursday, May 23rd. They noted that the move was a valuation call. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $106.43.
Several institutional investors have recently made changes to their positions in BPMC. FMR LLC boosted its holdings in Blueprint Medicines by 5.3% in the first quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock worth $555,491,000 after acquiring an additional 346,738 shares in the last quarter. OppenheimerFunds Inc. boosted its holdings in Blueprint Medicines by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 1,710,895 shares of the biotechnology company’s stock worth $136,957,000 after acquiring an additional 5,720 shares in the last quarter. Norges Bank bought a new position in Blueprint Medicines in the fourth quarter worth approximately $42,705,000. Eagle Asset Management Inc. boosted its holdings in Blueprint Medicines by 0.3% in the first quarter. Eagle Asset Management Inc. now owns 763,908 shares of the biotechnology company’s stock worth $61,150,000 after acquiring an additional 2,639 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Blueprint Medicines by 6.6% in the fourth quarter. Geode Capital Management LLC now owns 492,662 shares of the biotechnology company’s stock worth $26,559,000 after acquiring an additional 30,499 shares in the last quarter. Institutional investors own 97.45% of the company’s stock.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.